PwC came to this conclusion after conducting 23 interviews from February through May with health industry executives, health benefits experts and health plan actuaries. The leaders’ companies represent more than 90 million employer-sponsored large group members.
PwC identified four main factors that are likely to inflate or deflate costs in 2021. The two inflators are an uptick in mental health utilization and new specialty drugs. The two deflators are telehealth services replacing in-person visits and employers increasingly narrowing their provider networks.
“Uncertainty remains about the impacts of COVID-19 and the economic downturn on healthcare spending in 2021,” the report said. “The health of the overall population could worsen slightly as individuals delay needed care in the midst of the pandemic, pushing up future healthcare costs. The number of individuals with employer-sponsored insurance is declining, driving down provider revenues that have already taken a hit from COVID-19. Looking beyond spending, COVID-19 and the resulting economic downturn likely will transform aspects of the healthcare system.”
View the full report here.
More articles on healthcare finance:
42 hospitals closed, filed for bankruptcy this year
Cleveland Clinic cancels raises, faces $500M revenue shortfall
Michigan Medicine to lay off 738 employees by end of June
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
